Targeting a relapse causing protein to treat childhood acute myeloid leukaemia
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.
Finding out which changes to how DNA is read in neuroblastoma can give doctors more information about the cancer, and investigating whether these changes could be stopped through medicines.
Looking at how medulloblastoma brain tumours use an amino acid, and whether blocking access to that resource would make cancer cells more susceptible to treatment.
Investigating whether giving a medicine before doxorubicin cancer treatment could prevent heart damage.
Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.
Using two drugs to prevent an essential Wilms tumour protein interacting with a growth-promoting protein, and testing this treatment in patient samples.
Investigating how cancer cells can keep dividing and why this makes it harder to treat.
Finding the biological differences between teenage and young adult cancers cells compared to older adults.